导师介绍
| 姓名 | 汪少伯 | 性别 | 男 |
| 民族 | 汉族 | 导师层次 | 硕士生导师 |
| 职称 | 研究员 | 导师类型 | 学术型 |
| 学历 | 研究生 | 学位 | 博士 |
| 行政职务 | 无 | 邮箱 | wang_shaobo@gzlab.ac.cn |
| 招生方向 | |||
汪少伯，广州实验室感染与免疫研究部研究员，广州医科大学呼吸疾病全国重点实验室PI/特聘教授，广东省和广州市重大人才项目入选者（青年）。2017年于中国科学院大学武汉病毒研究所获博士学位，随后在美国加州大学圣迭戈分校从事博士后研究。2022年5月加入广州国家实验室，组建独立研究团队。
主要研究方向为呼吸道病毒的传播规律，具体围绕游离病毒入侵和病毒细胞间传播这两种基本形式，系统解析其传播过程中的共性规律与个性特征；在此基础上，进一步聚焦两种传播形式共同依赖的膜融合这一核心过程，深入探究其分子机制；最终以膜融合机制为靶标，研发广谱抗病毒新策略，并建立通用的病毒感染动物模型。研究成果以通讯作者或第一作者（含共同）在Nature Microbiology, The EMBO Journal, PNAS, Acta Pharmaceutica Sinica B, Nucleic Acids Research, Cell Reports, mBio (x2), Emerging Microbes & Infections (x3), Journal of Virology (x2)等综合和专业期刊上发表16篇论文；以共同作者在Nature Communications, EMBO Reports, Journal of Medicinal Chemistry等专业期刊上发表SCI论文18篇，总引用超1800次（谷歌学术），H index为21。其中, 新冠相关工作被JAMA特别推荐和介绍；寨卡病毒相关工作被同期Cell Stem Cell刊登评述文章推荐和高度评价；在抗病毒药物领域，获得授权国家发明专利4项。
1. 流感病毒、冠状病毒等游离病毒入侵和病毒细胞间传播的共性规律和个性特征；
2. 冠状病毒膜融合分子机制及其应用；
3. 广谱抗呼吸道病毒新策略开发。
1、Ran W#, Yang J#, Yu S#, Hu Q#, He Y#, Wang S. Wei C, Sun J, Zhu A, Li F, Zhang L, Li P, Hu H, Pan R, Yu Y, Yuan Y, Sun L, Wang Y, Zhang Z, Chen Z, Liu D, Yan Q, Wang D, Yu K, Wang Y, Zhuo J, Zhuang Z, Tao H, Zeng Q, Zhou K, Chen F, Tang W, Zhou Y, Bai R, Xu Y, Li N, Dai J, Zhao H, Park JE, Wang T, Ding Q*, Perlman S*, Zhao J*, Mao Y*, Wang S*, Zhao J*. Interferon-stimulated gene GALNT2 restricts respiratory virus infections. Nature Microbiology. 2026;11(1):256-270.
2、Wang S#, Li W#, Hui H, Tiwari SK, Zhang Q, Croker BA, Rawlings S, Smith D, Carlin AF, Rana TM*. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. The EMBO J. 2020;39(21), e106057.
3、Wang L#, Wang S#, Wu L, Li W, Bray W, Clark AE, Gonzalez GM, Wang Y, Carlin AF, Rana TM*. PCIF1-mediated deposition of 5'-cap N6, 2'-O-dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection. Proceedings of the National Academy of Sciences. 2023;120 (5), e2210361120.
4、Ai Q#, Hu H#, Ma K#, Wang Q, Huang S, Lu Y, Qi N, Shang J*, Du Rui*, Wang S*. Identification of FDA-approved IMPDH inhibitors boosting the broad-spectrum antiviral potential of ribavirin through depleting cellular GTP pool. Acta Pharmaceutica Sinica B. 2026.
5、Zhang Q#, Wang S#, Li W, Yau E, Hui H, Singh P, Achuthan V, Karris M, Engelman A, Rana TM*. Genome-wide CRISPR/Cas9 transcriptional activation screen identifies a histone acetyltransferase inhibitor complex as a regulator of HIV-1 integration. Nucleic Acids Research. 2022;50 (12), 6687-6701.
6、Wang S#, Zhang Q#, Tiwari SK#, Lichinchi G, Yau EH, Hui H, Li W, Furnari F, Rana TM*. Integrin alphavbeta5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy. Cell Reports. 2020;969-983.e4. (Highlighted by a Preview from Cell Stem Cell)
7、Wang S#, Li W#, Wang L, Tiwari SK, Bray W, Wu L, Li N, Hui H, Clark AE, Zhang Q, Zhang L, Carlin AF, Rana TM*. Interferon-Inducible Guanylate-Binding Protein 5 Inhibits Replication of Multiple Viruses by Binding to the Oligosaccharyltransferase Complex and Inhibiting Glycoprotein Maturation. mBio. 2025;16(12):e0293025.
8、Zhang LJ#, Wang S#, Xia L, Lv C, Tang HW, Liang Z, Xiao G*, Pang DW*. Lipid-Specific Labeling of Enveloped Viruses with Quantum Dots for Single-Virus Tracking. mBio. 2020;11(3):e00135-20.
9、Hu H#, Wang Q#, Ai Q#, Zhou P, He Y, Ye Z, Ma K, Zhou M, Huang S, Wang L, Qi N, Xiao G, Wang S*. FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine de novo synthesis. Emerging Microbes & Infections. 2026;15(1):2640289.
10、Huang J#, Ma K, Ding S, Wang Y, Xiong J, Yi J, Zhang J, He Z, Huang L, Ren X, Zhou J, Chen X, Liu L, Qi W*, Wang S*, Liao M*. A CRISPR activation screen identifies CH25H as a restriction factor against influenza viruses by targeting accessible cholesterol. Emerging Microbes & Infections. 2026;15(1):2651464.
11、Wang S#, Zhang Q#, Hui H, Agrawal K, Karris MAY, Rana TM*. An atlas of immune cell exhaustion in HIV-infected individuals revealed by single-cell transcriptomics. Emerging microbes & infections. 2020;9(1), 2333-2347.
12、Guo D#, Yu S#*, Ma K#, Tao H#, Wang Q, Han S, Ai Q, Hu H, Ma X, Li G, Wang S*. Concanavalin A Targets Phylogenetically Conserved N-Linked Glycans on Coronavirus Spike Proteins for Broad-Spectrum Antiviral Activity. Journal of Virology. 2026;100(5):e0167925.
13、Wang S#, Liu Y, Guo J, Wang P, Zhang L, Xiao G, Wang W*. Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection. Journal of Virology. 2017;91(21):e01055-17. (Faculty 1000 Recommendation)
14、Chen J#, Guo D#, Guo X, Zhao L, Li G, Liu H, Wang S*, Lao Z*, Zhu M*. Broad-spectrum inhibition of SARS-CoV-2 variants by dibutyl phthalate through allosteric disruption of Spike-ACE2 interface. Frontiers in Microbiology. 2026;16:1610775.
15、Yu S#, Hu H, Ai Q, Bai R, Ma K, Zhou M, Wang S*. SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Viruses. 2023;15(3):639.
16、Wang S#, Liu H, Zu X, Liu Y, Chen L, Zhu X, Zhang L, Zhou Z, Xiao G*, Wang W*. The ubiquitin-proteasome system is essential for the productive entry of Japanese encephalitis virus. Virology. 2016;498:116-127.
